chapter 31 anti-parkinson agents. copyright 2007 thomson delmar learning, a division of thomson...

Post on 31-Dec-2015

228 Views

Category:

Documents

6 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Chapter 31

Anti-Parkinson Agents

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 2

Parkinson’s Disease

A neurological disorder characterized by:

Muscle tremors Muscle rigidity Lack of coordination Drooling Shuffling gait Postural changes

(continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 3

Parkinson’s Disease

Imbalance of dopamine and acetylcholine levels in the brain

Levels of other neurological chemical decrease:

Gamma-aminobutyric acid (GABA) Serotonin Norepinephrine

(continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 4

Classes of Anti-Parkinson Agents

Dopaminergic agents Anticholinergic agents Catechol-O-methyltransferase inhibitors

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 5

Levodopa

Dopaminergic agent Most effective drug treatment Acts peripherally Rapidly converts to dopamine Symptoms subside or disappear

(continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 6

Levodopa

Therapeutic effects Therapeutic intensity varies Dosage dependent

Adverse effects Nausea and vomiting Orthostatic hypotension Cardiac arrhythmias

(continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 7

Carbidopa/Levodopa (Sinemet)

Carbidopa prevents levodopa from being broken down in the peripheral circulation

Improves neurological-skeletal muscle activity

Combining these agents reduces the required Levodopa dose by 25%

Given in Carbidopa, 10 mg / Levodopa,100 mg dose

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 8

Amantadine (Symmetrel)

Treats viral disorders such as influenza Acts as an anti-Parkinson agent; it

exerts an additive effect on Levodopa Increases CNS dopamine concentration

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 9

Anticholinergic Agents

Reduces excessive cholinergic brain activity

Example: trihexyphenidyl (Artane) Used for clients with minimal symptoms Adjunct with other agents

• Caution: narrow-angle glaucoma

(continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 10

Anticholinergic Agents

Apomorphine (Apokyn) Morphine-like substance

Old, but new No analgesic or addictive qualities Increases dopamine activity

(continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 11

Newest class of anti-Parkinson drug agents

Treats clients with history of poor response to levodopa

Sustains dopaminergic levels Brain remains stimulated

(continues)

Catechol-O-Methyltransferase

Inhibitors

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved.

31 - 12

Catechol-O-Methyltransferase

Inhibitors Adverse effects Liver failure Dyskinesia Orthostatic hypotension Dystonia Somnolence GI irritation

(continued)

top related